Vaccines and the Infectious Diseases They Prevent

Image representing the teeth of a bat with IMOVAX RABIES and IMOGRAM RABIES-HT writen below

Vaccination Recommendations

IMage of a chart representing a Post-exposure vaccination schedule for those who have NOT been exposed to rabies, but are at risk due to their occupation or travel plans

Pre-exposure immunization does not eliminate the need for prompt treatment following exposure to rabies¹

Pre-exposure vaccination merely simplifies post-exposure treatment by eliminating the need for IMOGAM Rabies–HT Immune Globulin and decreasing the number of IMOVAX Rabies vaccine doses¹

IMOVAX Rabies vaccine should be administered intramuscularly (IM) only

IMage of a chart representing a Post-exposure vaccination schedule for those who have been exposed to rabies, but have NOTreceived pre-exposure vaccination

IMage of a chart representing a Post-exposure vaccination schedule for those who have been exposed to rabies, and have received pre-exposure vaccination

Whether a person has received pre-exposure vaccination or not, anyone exposed to the rabies virus MUST receive post-exposure treatment¹

View full Prescribing Information for IMOVAX Rabies vaccine.

References: 1. Centers for Disease Control and Prevention (CDC). Human rabies prevention—United States, 1999: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 1999;48:1-21. 2. CDC. Travelers’ Health: Rabies. Available at: http://www2.ncid.cdc.gov/travel/yb/utils/ybGet.asp?section=dis&obj=rabies.htm. Accessed February 22, 2007.

IMOVAX® Rabies

Indication

IMOVAX Rabies vaccine is indicated for active, pre- and post-exposure immunization against rabies.

Safety Information
The most common local and systemic adverse reactions to IMOVAX Rabies vaccine may include injection site pain, erythema, and swelling; headache, nausea, and muscle aches. Other adverse reactions may occur. Once initiated for post-exposure treatment rabies vaccination should not be interrupted or discontinued because of mild local or systemic adverse reactions. Usually such reactions can be successfully managed with anti-inflammatory and antipyretic agents. Vaccination with IMOVAX Rabies vaccine may not protect all individuals.

Before administering IMOVAX Rabies vaccine, please see accompanying full Prescribing Information.

IMOGAM® Rabies–HT

Indication
IMOGAM Rabies-HT immune globulin is given for passive immunization of individuals suspected of exposure to rabies.

Safety Information
Side effects to the IMOGAM Rabies-HT immune globulin include injection site tenderness, pain, and muscle soreness or stiffness. Other side effects may occur. IMOGAM Rabies-HT immune globulin should not be given in repeated doses once vaccine treatment has begun. IMOGAM Rabies-HT immune globulin is made from components of human blood and, therefore, this vaccine may carry a risk of transmitting infectious material, although careful selection of donors and extensive testing are intended to minimize this risk. Treatment with a rabies immune globulin may not protect all individuals.

For more information about IMOGAM Rabies-HT immune globulin, talk to your health-care professional.

Last modified: 5/2/08